AI Generated Image
Moderna, Merck breakthrough could usher in wave of cancer vaccines
CNN • • business
Key Points:
- Merck and Moderna have developed a personalized mRNA cancer vaccine combined with Keytruda that significantly reduces melanoma recurrence and spread, showing promising results in a large trial with over 1,000 patients.
- Unlike chemotherapy or general immunotherapy, this vaccine trains the immune system to target specific tumor mutations, potentially offering a more precise and less harmful treatment option.
- The success in melanoma has spurred ongoing and planned trials targeting other cancers such as non-small cell lung cancer, bladder, kidney, pancreatic, stomach, and colon cancers, with results expected over the next several years.
- The combination treatment showed no new side effects beyond those typical of Keytruda alone, and earlier data indicated a substantial reduction in cancer recurrence and metastasis risk.
- Experts view this advancement as a major breakthrough validating mRNA technology for cancer treatment, with hopes it will transform cancer therapy across multiple tumor types.
